Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences

Share

SAN DIEGO, Aug. 21, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, immuno-oncology and beyond, will be participating in the following upcoming investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference in New York, N.Y.
    • Dates: September 4-6, 2024
      • Fireside chat to be held Friday, September 6 at 10:45 a.m. EDT
    • Replicate participants: Nathaniel Wang, Ph.D., CEO; Rachael Lester, CBO

  • Cantor Global Healthcare Conference in New York, N.Y.
    • Dates: September 17-19, 2024
    • Replicate participants: Nathaniel Wang, Ph.D., CEO; Rachael Lester, CBO

Replicate leadership will also present at the following upcoming scientific meetings:

  • RNA Leaders USA Congress in San Diego, Calif.
    • Keynote panel title: Scaling RNA Therapies to Deliver on the Promise of Precision Medicine
    • Presenter: Nathaniel Wang, Ph.D., CEO
    • Date and time: Wednesday, September 4, 2024 at 9:55 a.m. PDT

    • Presentation title: Next-Generation Self-Replicating RNA Drives Major Improvements to Clinical Bioactivity while Retaining a Strong Safety Profile
    • Presenter: Nathaniel Wang, Ph.D., CEO
    • Date and time: Wednesday, September 4, 2024 at 4:25 p.m. PDT

  • 3rd Non-Viral RNA Delivery Systems Summit in Boston, Mass.
    • Presentation title: LNP & Polymer Delivery of Self-Replicating RNA: Unlocking the Potential of Low Dose RNA Vaccines & Gene Therapy
    • Presenter: Andy Geall, Ph.D., CDO
    • Date and time: Thursday, October 3, 2024 at 9:30 a.m. EDT

About Replicate Bioscience
Replicate Bioscience is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved tolerability. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA vaccine in Phase 1 trials. Funded by Apple Tree Partners, Replicate is advancing a robust pipeline of srRNA vaccines and therapeutics, fueled by its proprietary library of customizable viral vectors. With deep expertise in srRNA and end-to-end development capabilities, Replicate is uniquely positioned to expand the reach of RNA treatments toward widespread use in infectious disease, immunology, immuno-oncology and more. Visit us at www.replicatebioscience.com.